Helpline
0800 121 8721
Email us
Fundraising Donate

Nivolumab-ipilimumab combination shows promise for kidney cancer brain metastases

Home/Drug treatments/Nivolumab-ipilimumab combination shows promise for kidney cancer brain metastases

Nivolumab-ipilimumab combination shows promise for kidney cancer brain metastases

21 Jun 2019

Tags
brain metastases ipilimumab nivolumab Opdivo renal cell carcinoma Yervoy
Listen to this News
Print this News

Share this Page:

FacebookTwitterLinkedInWhatsAppTumblrPinterestVkXingEmail

An interim analysis of study Checkmate 920 has shown that patients with advanced renal cell carcinoma (RCC) and brain metastases may benefit from treatment with the ipilimumab/nivolumab combination therapy. The results from this interim analysis were presented at the 2019 American Society of Clinical Oncology (ASCO) in Chicago earlier this month.

Read more in Cancer Therapy Advisor here

Listen to this News
Print this News

Share this Page:

FacebookTwitterLinkedInWhatsAppTumblrPinterestVkXingEmail

Kidney cancer news

23 Apr 2024

Sick pay - cancer patients are counting the cost

Read More

22 Apr 2024

Lenvatinib plus everolimus for patients with metastatic kidney cancer

Read More

22 Apr 2024

Adjuvant pembrolizumab prolongs overall survival for kidney cancer patients

Read More

17 Apr 2024

Cancer52 manifesto launch

Read More

12 Apr 2024

Immunotherapy combinations versus TKIs for papillary renal cell carcinoma

Read More

9 Apr 2024

CAR T cell immunotherapy shows promise for patients with kidney cancer

Read More

9 Apr 2024

Real world data on the use of cabozantinib plus immunotherapy in the second line

Read More

25 Mar 2024

How to manage anxiety and depression when you have kidney cancer

Read More

12 Mar 2024

Immunotherapy improves survival in kidney cancer patients with brain metastases

Read More

8 Mar 2024

Radiotherapy for the management of renal medullary carcinoma

Read More

8 Mar 2024

Manchester patient focus group

Read More

8 Mar 2024

NICE approves cabozantinib plus nivolumab for advanced kidney cancer

Read More

Most used tags

renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo sunitinib Sutent cabozantinib progression-free survival NHS England biomarkers ipilimumab Cabometyx pembrolizumab COVID-19 axitinib cancer survival non-clear cell kidney cancer VEGF inhibitors kidney cancer Inlyta coronavirus Yervoy risk factors Keytruda adjuvant therapy metastases targeted therapy papillary RCC everolimus biological markers Afinitor cancer outcomes ASCO first-line treatment NICE

Archives

Address

Action Kidney Cancer

11th Floor
3 Piccadilly Place
Manchester M1 3BN

Helpline

0800 121 8721
Email Us

About Action Kidney Cancer

We are the UK’s largest and most active patient-led kidney cancer charity. Whether you are a patient, survivor or someone you know has been diagnosed with kidney cancer, you have come to the right place to find support and information, and to be part of a caring and knowledgeable community of people: We are here to help you.
Registered charity in England, Wales (1164238), and Scotland (SC051330).
© Copyright Action Kidney Cancer 2021

Links

Home

About us

Donate

Contact us

Our partners

Branding by Kingswood Marketing

Policies

Website Policies

Complaints Policy

Equal Opportunities Policy

Information Governance Policy

Social Media Policy

Health Information Policy

Follow

X-Twitter
Our Website Design Specialist | Douglass Digital

Helpline: 0800 121 8721

support@actionkidneycancer.org

Go to Top